Drug Profile
Research programme: anticancer therapeutics - GVK Biosciences/Traws Pharma
Alternative Names: GBO-006; ON 1231320Latest Information Update: 04 Apr 2024
Price :
$50
*
At a glance
- Originator GVK BIO; Onconova Therapeutics
- Developer GVK BIO; Traws Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Polo-like kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Triple negative breast cancer
Most Recent Events
- 02 Apr 2024 Trawsfynydd Therapeutics has merged with Onconova Therapeutics to form Traws Pharma
- 28 May 2019 No recent reports of development identified for preclinical development in Cancer in USA
- 28 May 2019 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in USA